Lacouture Mario E, Boerner Scott A, Lorusso Patricia M
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 48201, USA.
Clin Lung Cancer. 2006 Dec;8 Suppl 1:S36-42. doi: 10.3816/clc.2006.s.012.
Many novel targeted agents have emerged against a variety of malignancies. Although papulopustular rash is the most commonly observed side effect associated with many of these agents, several non-rash skin toxicities have been identified that frequently result in the delay or discontinuation of anticancer therapy. These toxicities include skin hyperpigmentation, xerosis, pruritus, hair growth and color abnormalities, periungual and nail alterations, and hand-foot skin reaction. It is important to recognize these toxicities, so that they can be diagnosed early and treatment or dose modification can be initiated, if necessary. This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment.
针对多种恶性肿瘤出现了许多新型靶向药物。尽管丘疹脓疱性皮疹是与其中许多药物相关的最常见副作用，但已发现几种非皮疹性皮肤毒性，这些毒性常常导致抗癌治疗的延迟或中断。这些毒性包括皮肤色素沉着、皮肤干燥、瘙痒、毛发的生长和颜色异常、甲周和指甲改变以及手足皮肤反应。认识到这些毒性很重要，以便能够早期诊断，并在必要时启动治疗或调整剂量。本文综述了靶向治疗药物引起的几种非皮疹性皮肤毒性及其诊断和治疗指南。
